Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitas c, lėtinis - antivirusiniai vaistai sisteminiam naudojimui - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 ir 5. hepatito c viruso (hcv) genotipo-konkrečios veiklos, žr. skirsnius 4. 4 ir 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitas c, lėtinis - antivirusiniai vaistai sisteminiam naudojimui - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (žr. skirsnius 4. 2, 4. 4 ir 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 ir 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabine, tenofovir alafenamide, fumarate - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (žr. 5 skyrių.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib dinatrio - trombocitopenija - kiti sisteminės hemostatics - tavlesse fluorouracilu ir folino lėtinių imuninė trombocitopenija (ipp) suaugusių pacientų, kuriems yra ugniai atsparios kitiems gydymo.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - miego inicijavimo ir priežiūros sutrikimai - psicholeptikai - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.